SSXB8 Inhibitors
SSXB8 inhibitors represent a category of chemical agents that specifically target the SSXB8 protein, a molecular entity within a larger biochemical framework. The SSXB8 protein is a part of a complex cellular machinery, which plays a critical role in various biological processes. The inhibitors designed to target this protein are crafted through a nuanced understanding of molecular biology and organic chemistry, ensuring their ability to interact with the precise active sites or allosteric sites on the SSXB8 protein. This interaction is typically characterized by the inhibitor's affinity for the protein, the specificity with which it binds, and the consequent alteration in the protein's functional state. The structural composition of SSXB8 inhibitors is diverse, ranging from small molecules to more complex organic compounds, each with unique physicochemical properties that govern their interaction with the SSXB8 protein.
The development of SSXB8 inhibitors involves intricate design strategies that incorporate principles of medicinal chemistry, such as structure-activity relationships (SAR). Researchers utilize advanced techniques like X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and computational modeling to elucidate the three-dimensional structure of the SSXB8 protein and to identify key binding domains. This information is crucial for the rational design of inhibitors that can achieve high selectivity for the SSXB8 protein, which is essential for their function. These inhibitors often contain functional groups that enable them to engage in various types of chemical interactions with amino acid residues within the protein's binding pocket, such as hydrogen bonding, hydrophobic interactions, and ionic interactions. The fine-tuning of these interactions is paramount for the development of inhibitors with optimal binding characteristics. Furthermore, the physicochemical properties of these inhibitors, such as their solubility, stability, and molecular weight, are also meticulously optimized to enhance their efficacy in interacting with the SSXB8 protein.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that can prevent the degradation of ubiquitinated proteins. Inhibition of the proteasome could lead to the accumulation of regulatory proteins that control the cell cycle, and apoptosis, potentially reducing the activity of SSXB8 by promoting the degradation of factors that stabilize or activate it. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that specifically targets BCR-ABL, c-Kit, and PDGFR. By inhibiting these kinases, imatinib can indirectly reduce downstream signaling that may be necessary for the activation or stabilization of SSXB8. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that impairs the PI3K/AKT signaling pathway. This pathway is often involved in cell survival and growth, and its inhibition could downregulate cellular processes that are required for the proper functioning and activation of SSXB8. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that can disrupt the mTORC1 signaling pathway, which affects cellular growth and metabolism. By inhibiting this pathway, rapamycin may decrease the synthesis of proteins that act upstream of SSXB8, resulting in its reduced activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor that interferes with the MAPK/ERK pathway, a key regulatory pathway for cell proliferation and differentiation. Inhibition of MEK may lead to altered expression of transcription factors and other proteins that influence SSXB8 activity. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an EGFR inhibitor that blocks the epidermal growth factor receptor (EGFR) tyrosine kinase. By doing so, it can decrease the activation of downstream signaling pathways that may be essential for the function of SSXB8. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a CDK4/6 inhibitor that impedes cell cycle progression from G1 to S phase. Its action may lead to reduced transcription and translation of proteins that modulate the activity of SSXB8. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor, which can lead to changes in chromatin structure and gene expression. By altering gene expression, it might indirectly decrease the expression of genes encoding proteins that activate SSXB8. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which acts upstream of ERK in the MAPK pathway. By inhibiting this pathway, PD98059 can reduce the phosphorylation and activity of proteins that may regulate SSXB8 function. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that targets RAF kinases, VEGFR, and PDGFR. The inhibition of these kinases could decrease signaling pathways that promote the functional activity of SSXB8. | ||||||